Performance comparison of an in-house integrase genotyping assay versus the ViroSeq™ Integra48, and study of HIV-1 integrase polymorphisms in Hong Kong

Journal of Clinical Virology

Volumn 58, Issue 1, 2013, Pages 299-302

  To, Sabrina Wai Chi ^a   Chen, Jonathan Hon Kwan ^a   Wong, Ka Hing ^b   Chan, Kenny Chi Wai ^b   Ng, Hon Man ^a   Wu, Hao ^a   Lam, Jason Tszhin ^a   Yam, Wing Cheong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

CRF01_AE; In house; Integrase genotyping; Integrase polymorphisms; Integrase resistance; Versus ViroSeq Integra48

Indexed keywords

ANTIRETROVIRUS AGENT; INTEGRASE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; FEMALE; GENETIC POLYMORPHISM; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS TYPING;

EID: 84881541888     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.06.040     Document Type: Article

References (23)

1. Fransen S., Gupta S., Danovich R., Hazuda D., Miller M., Witmer M., et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009, 83:11440-11446.
2. Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008, 359:355-365.
3. Charpentier C., Karmochkine M., Laureillard D., Tisserand P., Belec L., Weiss L., et al. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008, 9:765-770.
4. Delelis O., Malet I., Na L., Tchertanov L., Calvez V., Marcelin A.G., et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 2009, 37:1193-1201.
5. Garrido C., Geretti A.M., Zahonero N., Booth C., Strang A., Soriano V., et al. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010, 65:320-326.
6. Brenner B.G., Lowe M., Moisi D., Hardy I., Gagnon S., Charest H., et al. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol 2011.
7. Dimonte S., Babakir-Mina M., Aquaro S., Perno C.F. Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naive infected individuals. Infection 2013.
8. Chen J.H.K., Wong K.H., Chen Z.W., Chan K., Lam H.Y., To S.W.C., et al. Increased genetic diversity of HIV-1 circulating in Hong Kong. PLoS ONE 2010, 5.
9. Chen J.H.K., Wong K.H., Chan K., Lam H.Y., Lee S.S., Li P., et al. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping. J Clin Virol 2007, 39:125-131.
10. de Oliveira T., Deforche K., Cassol S., Salminen M., Paraskevis D., Seebregts C., et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005, 21:3797-3800.
11. Van Laethem K., Schrooten Y., Covens K., Dekeersmaeker N., De Munter P., Van Wijngaerden E., et al. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods 2008, 153:176-181.
12. Liu T.F., Shafer R.W. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006, 42:1608-1618.
13. Staden R., Beal K.F., Bonfield J.K. The Staden package, 1998. Methods Mol Biol 2000, 132:115-130.
14. Rhee S.Y., Liu T.F., Kiuchi M., Zioni R., Gifford R.J., Holmes S.P., et al. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008, 5:74.
15. Steigbigel R.T., Cooper D.A., Teppler H., Eron J.J., Gatell J.M., Kumar P.N., et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMARK 1 and 2 phase III trials. Clin Infect Dis 2010, 50:605-612.
16. Yazdanpanah Y., Fagard C., Descamps D., Taburet A.M., Colin C., Roquebert B., et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009, 49:1441-1449.
17. Chen J.H.K., Wong K.H., Chan K.C.W., To S.W.C., Chen Z.W., Yam W.C. Phylodynamics of HIV-1 subtype B among the men-having-sex-with-men (MSM) population in Hong Kong. PLoS ONE 2011, 6.
18. Goethals O., Vos A., Van Ginderen M., Geluykens P., Smits V., Schols D., et al. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 2010, 402:338-346.
19. Malet I., Delelis O., Valantin M.A., Montes B., Soulie C., Wirden M., et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008, 52:1351-1358.
20. Phuphuakrat A., Pasomsub E., Kiertiburanakul S., Chantratita W., Sungkanuparph S. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates. AIDS Res Hum Retroviruses 2012, 28:937-943.
21. Nouhin J., Donchai T., Hoang K.T., Ken S., Kamkorn J., Tran T., et al. Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study. Infect Genet Evol 2011, 11:38-43.
22. da Silva D., Van Wesenbeeck L., Breilh D., Reigadas S., Anies G., Van Baelen K., et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010, 65:1262-1269.
23. Sichtig N., Sierra S., Kaiser R., Daumer M., Reuter S., Schulter E., et al. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother 2009, 64:25-32.